Next Article in Journal
Trichosanthis Semen Suppresses Lipopolysaccharide-Induced Neuroinflammation by Regulating the NF-κB Signaling Pathway and HO-1 Expression in Microglia
Next Article in Special Issue
The Cytotoxic Necrotizing Factors (CNFs)—A Family of Rho GTPase-Activating Bacterial Exotoxins
Previous Article in Journal
Keeping Lagocephalus sceleratus off the Table: Sources of Variation in the Quantity of TTX, TTX Analogues, and Risk of Tetrodotoxication
Previous Article in Special Issue
Helicobacter pylori CagA EPIYA Motif Variations Affect Metabolic Activity in B Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 13
Issue 12
10.3390/toxins13120897
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet?

by
Min Tang-Fichaux
1,
Priscilla Branchu
1,
Jean-Philippe Nougayrède
1 and
Eric Oswald
1,2,*
1
IRSD, Université de Toulouse, INSERM, INRAE, ENVT, UPS, 31024 Toulouse, France
2
Service de Bactériology-Hygiène, Hôpital Purpan, CHU de Toulouse, 31059 Toulouse, France
*
Author to whom correspondence should be addressed.
Toxins 2021, 13(12), 897; https://doi.org/10.3390/toxins13120897
Submission received: 16 November 2021 / Revised: 1 December 2021 / Accepted: 8 December 2021 / Published: 14 December 2021
(This article belongs to the Special Issue Toxins: The New Frontier for Understanding the Barrier between Commensalism and Pathogenicity?)
Browse Figures
Versions Notes

Abstract

:
Colibactin is a genotoxin produced primarily by Escherichia coli harboring the genomic pks island (pks+ E. coli). Pks+ E. coli cause host cell DNA damage, leading to chromosomal instability and gene mutations. The signature of colibactin-induced mutations has been described and found in human colorectal cancer (CRC) genomes. An inflamed intestinal environment drives the expansion of pks+ E. coli and promotes tumorigenesis. Mesalamine (i.e., 5-aminosalycilic acid), an effective anti-inflammatory drug, is an inhibitor of the bacterial polyphosphate kinase (PPK). This drug not only inhibits the production of intestinal inflammatory mediators and the proliferation of CRC cells, but also limits the abundance of E. coli in the gut microbiota and diminishes the production of colibactin. Here, we describe the link between intestinal inflammation and colorectal cancer induced by pks+ E. coli. We discuss the potential mechanisms of the pleiotropic role of mesalamine in treating both inflammatory bowel diseases and reducing the risk of CRC due to pks+ E. coli.
Keywords:
colibactin; polyphosphate kinase; mesalamine; inflammatory bowel disease; colorectal cancer
Key Contribution: This review of the literature shows that it would be possible to use a single drug to reduce the risk of colon cancer due to colibactin-producing pathobionts by acting on both the host and the bacteria.

1. Introduction

Escherichia coli is a ubiquitous intestinal commensal and one of the most frequently isolated organisms from clinical specimens. Of all E. coli strains, phylogenetic group B2 strains are increasingly found in the feces of healthy humans in high-income countries [1,2]. E. coli group B2 includes commensal strains and pathogenic strains that are responsible for extra-intestinal diseases, including urinary tract infections, sepsis, pneumonia, and neonatal meningitis. Among the strains of the B2 phylogroup, there are a large number of strains that possess in their genome the pks island that encodes the genotoxin colibactin [3,4]. These pks+ strains of E. coli are frequently found in asymptomatic carriage in the digestive tract from the first days after birth [5,6]. As we will show in this review, the intestinal genotoxicity of these bacteria greatly depends on the intestinal environment such as the presence of certain food contaminants [7], and especially on the inflammatory response, which suggests that these so-called commensal strains of E. coli are in fact true pathobionts.
The pks island encoding enzymes responsible for colibactin biosynthesis is mainly present in this group. The sequence of the pks island is highly conserved and pks-carrying (pks+) strains are found overwhelmingly capable to produce colibactin [3]. The biosynthesis of colibactin has been summarized in two nice reviews [8,9]. Colibactin is a secondary metabolite belonging to the chemical family of hybrid polyketide (PK)–non-ribosomal peptides (NRP). Colibactin directly damages host DNA both in vitro [10,11,12] and in vivo [5,13,14,15,16,17,18,19]. This genotoxin is linked to the virulence of pathogenic E. coli [15,17,20], intestinal microbial diversity [21] and intestinal homeostasis [5,22]. Importantly, accumulating evidence suggests that the pathobiont pks+ E. coli is associated with colorectal cancer (CRC) [10,16,18,23,24,25,26,27]. CRC is the third most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths worldwide, and its burden is expected to increase by 60% to more than 2.2 million new cases and 1.1 million annual deaths by 2030 [28]. CRC has long been known to be associated with chronic intestinal inflammation, such as inflammatory bowel disease (IBD) [29]. IBD is associated with gut microbiota dysbiosis, characterized by the increased abundance of facultative anaerobic Enterobacteriaceae that include pks+ E. coli [30].
Mesalamine (i.e., 5-aminosalycilic acid), an anti-inflammatory drug, has been in the first-line therapy for IBD for decades [31]. A long-term use of mesalamine has chemopreventive properties against CRC [32,33,34]. The exact mechanism of action of mesalamine is unknown. However, it has been shown that, on one hand, mesalamine inhibits host inflammatory cascades and inhibits the proliferation of CRC cells [35,36,37,38]. On another hand, mesalamine alters bacterial microbiota composition, which is characterized by the reduction of Enterobacteriaceae (e.g., E. coli) in inflamed mucosa [39,40]. Interestingly, mesalamine is an inhibitor of the bacterial polyphosphate kinase (PPK) [41]. PPK is essential for the synthesis of long-chain polyphosphate (polyP) [42]. The treatment with mesalamine decreases polyphosphate (polyP) levels in gut microbiota, which may sensitize bacteria to oxidative stress [43] and diminish bacterial persistence within the inflamed mucosa. We have recently shown that mesalamine directly reduces colibactin production by pks+ E. coli in a PPK-dependent/ independent manner [44]. In this review, we describe the association of pks+ E. coli and intestinal inflammation in the development of CRC, and we discuss the pleiotropic role of mesalamine in the prevention of CRC due to bacteria producing colibactin.

2. Pks+ E. coli Induce DNA Damage and Have a Mutational Impact in Colorectal Cancer

Unlike other genotoxins such as CDT, colibactin is not a proteinaceous “exotoxin” [45]. Colibactin is a hybrid PK-NRP compound which has a nearly symmetrical structure that contains two electrophilic cyclopropane warheads [46]. The warheads have a high binding-affinity for adenine residues within AAWWTT nucleotide motifs [10,27]. The warheads alkylate DNA on two adenine residues of opposite strands of DNA, resulting in DNA inter-strand cross-links (ICLs) [11,14,46,47]. How exactly the host cells repair colibactin-induced DNA damage and remove the ICLs remains to be studied, but ICLs are converted into DNA double-strand breaks (DSBs) during the DNA-damage response (DDR), or evolve directly to DSBs by depurination [48] (Figure 1).
DNA damage caused by colibactin has been observed in cellulo [10,11,12] and in mouse models of digestive or urinary tract colonization [5,13,14,15,16,17,18,19]. The consequences for cells infected by pks+ E. coli depend on the infection dose: A high infectious dose induces massive DNA damage, resulting in mitotic catastrophe and apoptosis [11,12,19], whereas a milder infectious dose induces persistent DNA damage and senescence [16,49]. With a low infectious dose, cells repair most of the damage and resume their cell cycle, but with the establishment of a chromosomal instability phenotype and a significant increase in gene mutation frequency [19] (Figure 1).
Recent reports have revealed the distinct mutational signature caused by pks+ E. coli (also called the colibactin footprint), and the same mutational signature has been detected in human cancer genomes, predominantly in CRC [10,27,50,51]. Among the common CRC driver mutations, 2.4–9% match the colibactin footprint, and the adenomatous polyposis coli (APC) gene APC (a tumor-suppressor gene) contains the highest number of mutation matches [10,27]. Nevertheless, we should recognize that the colibactin footprint in CRC genomes and corresponding driver genes may represent only the tip of the iceberg of the impact of pks+ E. coli [52]. A recent study has demonstrated that infection with pks+ E. coli fails to induce a typical colibactin mutational signature, but the genotoxic effect is sufficient to rapidly cause chromosomal aberrations in primary colon cells and to induce multiple features of transformation reminiscent of CRC [53]. This may be due to the failure of resolving ICL via repair machinery prior to mitosis. Consistent with this notion, we have indeed observed chromosomal aberrations after a short-time infection in vitro [19].
Collectively, these findings indicate the mutagenic potential of pks+ E. coli and its causative role in CRC. Nevertheless, we should also recognize that the presence of pks+ E. coli may be not enough for the development of CRC but exhibits its carcinogenic role under certain conditions such as inflammation.

3. Intestinal Inflammation, pks+ E. coli and Colorectal Cancer

3.1. Intestinal Inflammation Contributes to Colorectal Cancer

Intestinal inflammation is an important contributor to CRC formation [29,54]. Patients with IBD, such as Crohn’s disease (CD) or ulcerative colitis (UC), have a higher risk of developing CRC. These incidence rates of CRC in IBD patients correspond to cumulative probabilities of 2% by 10 years, 8% by 20 years, and 18% by 30 years [55]. The underlying mechanisms of the transition from inflammation to malignancy have not yet been fully understood. Nuclear factor kappa B (NF-κB), a key transcription factor that regulates immunological and inflammatory responses, has been identified as one of the main participants in this transition [56] (Figure 2). One of the main pro-inflammatory cytokines induced by NF-κB is interleukin 6 (IL-6), which activates the transcription factor STAT3 in intestinal epithelial cells (IECs) and then promotes tumorigenesis by facilitating their proliferation, the inhibition of apoptosis, and/ or other pro-tumorigenic pathways [57]. This IL-6-STAT3 signaling can also repress the tumor-suppressor miR-34a [58]. Another pro-inflammatory cytokine involved in NF-κB activation is tumor necrosis factor (TNF). Constitutive activation of Wnt induces the activation of TNF that enhances activation of NF-κB, resulting in the de-differentiation of IECs and facilitation of tumor initiation [59]. Moreover, mutation of the gene encoding p53 (Tp53), an early event in inflammation-associated CRC [60], causes NF-κB activation in IECs and surrounding stromal cells and induces epithelial–mesenchymal transition [61,62]. Constitutive activation of NF-κB induces DNA damage via the generation of reactive oxygen species (ROS) [63], which provides an additional link between chronic inflammation and tumorigenesis.

3.2. Intestinal Inflammation Promotes the Carcinogenic Activity of pks+ E. coli

While intestinal inflammation per se contributes to CRC, intestinal inflammation is associated with the perturbation of gut microbiota composition and activities, which can further promote inflammation and cancer development [65]. Here, we focus on discussing the pro-tumorigenic interplay between inflammation and pks+ E. coli. In mouse models of inflammation-associated CRC, pks+ E. coli have been shown to enhance tumorigenesis [16,18,26,66]. Inflammation is essential for pks+ E. coli-induced CRC, as pks+ E. coli failed to induce CRC in inflammation-resistant mice [67]. Inflammation could favor pks+ E. coli carcinogenic activity (i.e., colibactin-induced DNA damage in IECs) by facilitating pks+ E. coli expansion, enhancing their attachment to the mucosa, or/and increasing the expression of pks genes (Figure 2).
During intestinal inflammation, epithelial-derived ROS not only induce DNA damage as mentioned above, but also increase mucosal oxygenation, which favors the aerobic expansion of E. coli [68]. In addition to ROS, less oxygen consumption by IECs during inflammation also elevates mucosal oxygenation [64]. Peroxisome proliferator-activated receptor gamma (PPAR-γ) has a lower expression in IECs of IBD patients compared with healthy subjects [69,70]. PPAR-γ plays an important role in activating mitochondrial bioenergetics that causes high oxygen consumption, and thereby maintains epithelial hypoxia [71]. Therefore, a lower expression of PPAR-γ in IECs of IBD patients leads to a higher epithelial oxygenation that benefits the expansion of facultative anaerobes Enterobacteriaceae, including pks+ E. coli. Importantly, the aerobic expansion of pks+ E. coli is required for the cancer-inducing activity of this pathobiont in a mouse model of inflammation-associated CRC [24]. Moreover, the high-level production of inflammation-derived [72] nitrate and microbiota-derived formate [73] in the inflamed intestine also benefits the outgrowth of Enterobacteriaceae. It has been shown that the administration of tungstate blunts the expansion of Enterobacteriaceae to ameliorate colitis [74]. Further, it has been identified that tungstate treatment decreases the intestinal burden of pks+ E. coli, reduces DNA damage, and thereby lowers tumor incidences [75].
In addition to the E. coli expansion, the cancer-inducing activity of pks+ E. coli may also require mucosal invasion to have a direct contact with IECs, according to in vitro evidence that the genotoxicity of pks+ E. coli is cell-to-cell contact-dependent [12]. Interestingly, intestinal inflammation might favor the contact of pks+ E. coli to IECs by enhancing mucosal invasion of this pathobiont. Bacterial biofilms which can promote bacterial mucosal invasion are often found in patients with IBD or CRC [76,77]. Pks+ E. coli have shown a higher prevalence (68%) in mucosal biofilms from CRC patients than from healthy subjects [26]. Noticeably, pks+ E. coli are indeed more frequently found in stool or intestinal biopsy samples from IBD/CRC patients than from healthy subjects [18,26,78,79]. IBD patients as well as mouse models mimicking the human disease often show defects in intestinal barrier function, resulting in an increase of mucus penetration by bacteria [80]. Mucosal invasion may not only allow the translocation of colibactin from bacteria to IECs, but also help the invasion of some pks+ E. coli strains into host cells, which may exacerbate the inflammatory response, enhance bacterial persistence, and exacerbate genotoxicity. Raisch et al. has demonstrated that pks+ E. coli are able to resist killing by human THP-1 macrophages, to replicate intracellularly, and to persist inside host cells until at least 72 h after infection, which significantly increases the production of the protumoral factor cyclooxygenase-2 (COX-2) [81]. Still, whether intracellular pks+ E. coli cause DNA damage and induce a bystander effect requires future studies to identify.
In some cases, neither fecal nor tissue-associated pks+ E. coli abundance was significantly changed with inflammation, but the overall expression of the pks island was significantly higher when inflammation was higher [82]. This is consistent with another report which shows that the expression of pks genes (clbG, clbH, clbL, clbM and clbN) is upregulated in an inflamed environment [67]. The increased expression of pks genes could account for another role of inflammation in pks+ E. coli carcinogenic activity.
Altogether, these findings suggest that inflammation and pks+ E. coli synergistically promote CRC formation. Tumorigenesis is driven, at least partially, by selective enrichment or/and invasion of pks+ E. coli in the inflamed environment. Intestinal inflammation may also drive tumorigenesis by upregulating the expression of pks genes, presumably leading to more colibactin production, and thereby more DNA damage in the colon epithelium.

4. The Roles of Mesalamine in the Treatment of Inflammation and the Prevention of Cancer Promoted by pks+ E. coli

The anti-inflammatory drug mesalamine, a structural analogue of aspirin (Figure 3), is the first-line treatment of mild to moderate flares of UC and, especially, for maintenance of remission [83]. For off-label use, clinicians may use mesalamine in CD after surgical resection of the affected bowel. Moreover, long-term mesalamine therapy has been suggested for reducing the risk of IBD-related CRC [32,33,34].

4.1. Effects of Mesalamine on the Host

Mesalamine has direct effects on host cells (Figure 3). Mesalamine acts predominantly at the site of inflammation and its efficacy is dependent on achieving high intraluminal concentrations [84]. It has been shown that mesalamine downregulates the COX-2/PGE2 axis in inflammatory cells [85,86] and CRC cells [38]. Mesalamine arrests the growth and enhances the death of CRC cells in a COX-2-dependent/independent manner [38]. Moreover, it has been shown that mesalamine interferes with NF-κB activation in mouse colonic epithelial cells and CRC cells [87,88]. Furthermore, mesalamine has been shown to inhibit Wnt/β-catenin pathway both in CRC cells [89,90] and in vivo [91,92]. In addition to the inhibitory effects of mesalamine described above, mesalamine has been well known as a PPAR-γ agonist [37,70]; it has been shown to restore PPAR-γ in the colonic mucosa [93]. The mesalamine-driven PPAR-γ activation induces the apoptosis and growth inhibition of CRC cells [94].

4.2. Effects of Mesalamine on pks+ E. coli

Mesalamine treatment has effects not only on host cells, but also on bacteria. Here we focus especially on pks+ E. coli (Figure 3). So far, the most well-described direct effect of mesalamine on bacteria is the inhibition of bacterial PPK [41]. Our recent study has demonstrated that the inactivation of PPK by mutagenesis reduces the promoter activity of clbB (one of the essential enzymes for colibactin biosynthesis), and decreases the production level of colibactin [44]. We have therefore used mesalamine to treat pks+ E. coli and found the same effects than PPK inactivation. However, the production of colibactin in the mutant lacking PPK is further reduced by mesalamine, indicating that mesalamine is capable of inhibiting colibactin production independently from its inhibitory effect on PPK. Our results are consistent with an earlier report which shows that mesalamine inhibits the transcription of pks genes, and reduces DSBs caused by pks+ E. coli [95]. Thus, these results suggest that the chemopreventive effect of mesalamine, at least partially, relies on its inhibitory effect on colibactin production by pks+ E. coli, and thereby reduces DNA damage in IECs.
PPK, besides colibactin production, is also linked to many other important bacterial activities [42], e.g., resistance to oxidative stress [43] as well as biofilm formation and resistance to antibiotics [96]. Recent studies have even shown that polyP disturbs multiple macrophage functions for evading host immunity [97]. Mesalamine treatment sensitizes E. coli to inflammatory oxidant, reduces biofilm formation, and decreases bacterial persistence [41]. Mesalamine has also been shown to inhibit directly the growth of pks+ E. coli in aerobic conditions [39,95]. Moreover, instead of a direct inhibitory effect on bacteria, mesalamine limits the aerobic expansion of pks+ E. coli through an indirect way, whereby mesalamine-driven activation of PPAR-γ restores epithelium hypoxia [39]. Therefore, mesalamine could reduce pks+ E. coli carcinogenic activity not only by inhibiting the production of colibactin, but also by limiting pks+ E. coli colonization and invasion in an inflamed environment, presumably reducing the contact of pks+ E. coli to IECs.
Collectively, these data suggest that the chemopreventive effect of mesalamine not only depends on its ability to ameliorate the severity of inflammation, but also to inhibit the carcinogenic activity of pks+ E. coli.

5. Conclusions

Accumulating evidence indicates that pks+ E. coli is associated with CRC. Notably, an inflammation environment is required for the cancer-inducing activity of pks+ E. coli [16,18,26,66]. Intestinal inflammation favors the expansion and mucosal invasion of pks+ E. coli by increasing epithelial oxygenation [24], promoting bacterial biofilm formation [76], or decreasing mucosal barrier integrity [80]. Moreover, inflammation enhances the expression of pks genes [67,82]. In turn, pks+ E. coli strains exacerbate inflammation and induce DNA damage, and thereby promote tumorigenesis. Therefore, an efficient therapy to treat IBD and prevent CRC should include both anti-inflammation and anti-pks+ E. coli activities. The anti-inflammatory drug mesalamine has been used as a gold standard to treat UC and has been shown to prevent CRC. Additionally, non-steroidal anti-inflammatory drugs (NSAIDs), especially COX-2 inhibitors such as aspirin, are thought to be potentially valuable anti-tumor agents [98]. However, due to the potential harm to cardiovascular, renal, hepatic, and gastrointestinal tissues, the usage of NSAIDs should be cautious [99]. Given the involvement of gut microbiota composition and activities in CRC development, the impact of NSAIDs on the microbiota should be evaluated.
Mesalamine directly interferes with bacterial functions via inhibiting PPK enzyme activity and other unknown mechanisms. Mesalamine treatment not only diminishes the abilities of pks+ E. coli linked to persistence or invasion (i.e., resistance to oxidative stress, biofilm formation, and resistance to antibiotics) [41], but also reduces the genotoxicity of pks+ E. coli [44]. PPK, as the essential enzyme for long-chain polyP synthesis in bacteria, plays many important roles in various bacterial functions which have been summarized in a very nice, recent review [42] (Figure 4). Therefore, mesalamine may affect other PPK-associated abilities. Besides mesalamine, there are many other PPK inhibitors that have been identified [42,100]. These inhibitors may also be able to reduce the genotoxicity of pks+ E. coli, and might have the potential to reduce the risk of CRC development due to pks+ E. coli. In addition, if the PPK inhibitor also has an anti-inflammatory effect, it might be the next “mesalamine”, which could benefit patients who are intolerant to mesalamine.

Author Contributions

Conceptualization, E.O.; writing—original draft preparation, M.T.-F.; writing—review and editing, M.T.-F., P.B., J.-P.N. and E.O.; supervision, E.O.; funding acquisition, E.O. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by French National Agency for Research (ANR), grant number UTI-TOUL ANR-17-CE35-0010 and ANR-19-AMRB-0008.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments

The authors gratefully acknowledge other members in our team for critical revision.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Tenaillon, O.; Skurnik, D.; Picard, B.; Denamur, E. The population genetics of commensal Escherichia coli. Nat. Rev. Microbiol. 2010, 8, 207–217. [Google Scholar] [CrossRef] [PubMed]
  2. Massot, M.; Daubié, A.-S.; Clermont, O.; Jauréguy, F.; Couffignal, C.; Dahbi, G.; Mora, A.; Blanco, J.; Branger, C.; Mentré, F.; et al. Phylogenetic, virulence and antibiotic resistance characteristics of commensal strain populations of Escherichia coli from community subjects in the Paris area in 2010 and evolution over 30 years. Microbiology 2016, 162, 642–650. [Google Scholar] [CrossRef]
  3. Auvray, F.; Perrat, A.; Arimizu, Y.; Chagneau, C.V.; Bossuet-Greif, N.; Massip, C.; Brugère, H.; Nougayrède, J.-P.; Hayashi, T.; Branchu, P.; et al. Insights into the acquisition of the pks island and production of colibactin in the Escherichia coli population. Microb. Genom. 2021, 7, 000579. [Google Scholar] [CrossRef] [PubMed]
  4. Wami, H.; Wallenstein, A.; Sauer, D.; Stoll, M.; von Bünau, R.; Oswald, E.; Müller, R.; Dobrindt, U. Insights into evolution and coexistence of the colibactin- and yersiniabactin secondary metabolite determinants in enterobacterial populations. Microb. Genom. 2021, 7, 000577. [Google Scholar] [CrossRef]
  5. Payros, D.; Secher, T.; Boury, M.; Brehin, C.; Ménard, S.; Salvador-Cartier, C.; Cuevas-Ramos, G.; Watrin, C.; Marcq, I.; Nougayrède, J.-P.; et al. Maternally acquired genotoxic Escherichia coli alters offspring’s intestinal homeostasis. Gut Microbes 2014, 5, 313–325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Secher, T.; Brehin, C.; Oswald, E. Early settlers: Which E. coli strains do you not want at birth? Am. J. Physiol. Gastrointest. Liver Physiol. 2016, 311, G123–G129. [Google Scholar] [CrossRef] [Green Version]
  7. Payros, D.; Dobrindt, U.; Martin, P.; Secher, T.; Bracarense, A.P.F.L.; Boury, M.; Laffitte, J.; Pinton, P.; Oswald, E.; Oswald, I.P. The Food Contaminant Deoxynivalenol Exacerbates the Genotoxicity of Gut Microbiota. mBio 2017, 8, e00007-17. [Google Scholar] [CrossRef] [Green Version]
  8. Dougherty, M.W.; Jobin, C. Shining a Light on Colibactin Biology. Toxins 2021, 13, 346. [Google Scholar] [CrossRef]
  9. Faïs, T.; Delmas, J.; Barnich, N.; Bonnet, R.; Dalmasso, G. Colibactin: More Than a New Bacterial Toxin. Toxins 2018, 10, 151. [Google Scholar] [CrossRef] [Green Version]
  10. Pleguezuelos-Manzano, C.; Puschhof, J.; Rosendahl Huber, A.; van Hoeck, A.; Wood, H.M.; Nomburg, J.; Gurjao, C.; Manders, F.; Dalmasso, G.; Stege, P.B.; et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli. Nature 2020, 580, 269–273. [Google Scholar] [CrossRef]
  11. Bossuet-Greif, N.; Vignard, J.; Taieb, F.; Mirey, G.; Dubois, D.; Petit, C.; Oswald, E.; Nougayrède, J.-P. The Colibactin Genotoxin Generates DNA Interstrand Cross-Links in Infected Cells. mBio 2018, 9, e02393-17. [Google Scholar] [CrossRef] [Green Version]
  12. Nougayrede, J.-P.; Homburg, S.; Taieb, F.; Boury, M.; Brzuszkiewicz, E.; Gottschalk, G.; Buchrieser, C.; Hacker, J.; Dobrindt, U.; Oswald, E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006, 313, 848–851. [Google Scholar] [CrossRef] [PubMed]
  13. Chagneau, C.V.; Massip, C.; Bossuet-Greif, N.; Fremez, C.; Motta, J.-P.; Shima, A.; Besson, C.; Faouder, P.L.; Cénac, N.; Roth, M.-P.; et al. Uropathogenic E. coli induces DNA damage in the bladder. PLoS Pathog. 2021, 17, e1009310. [Google Scholar] [CrossRef] [PubMed]
  14. Wilson, M.R.; Jiang, Y.; Villalta, P.W.; Stornetta, A.; Boudreau, P.D.; Carra, A.; Brennan, C.A.; Chun, E.; Ngo, L.; Samson, L.D.; et al. The human gut bacterial genotoxin colibactin alkylates DNA. Science 2019, 363, eaar7785. [Google Scholar] [CrossRef]
  15. McCarthy, A.J.; Martin, P.; Cloup, E.; Stabler, R.A.; Oswald, E.; Taylor, P.W. The Genotoxin Colibactin Is a Determinant of Virulence in Escherichia coli K1 Experimental Neonatal Systemic Infection. Infect. Immun. 2015, 83, 3704–3711. [Google Scholar] [CrossRef] [Green Version]
  16. Cougnoux, A.; Dalmasso, G.; Martinez, R.; Buc, E.; Delmas, J.; Gibold, L.; Sauvanet, P.; Darcha, C.; Déchelotte, P.; Bonnet, M.; et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut 2014, 63, 1932–1942. [Google Scholar] [CrossRef]
  17. Marcq, I.; Martin, P.; Payros, D.; Cuevas-Ramos, G.; Boury, M.; Watrin, C.; Nougayrède, J.-P.; Olier, M.; Oswald, E. The Genotoxin Colibactin Exacerbates Lymphopenia and Decreases Survival Rate in Mice Infected With Septicemic Escherichia coli. J. Infect. Dis. 2014, 210, 285–294. [Google Scholar] [CrossRef] [Green Version]
  18. Arthur, J.C.; Perez-Chanona, E.; Mühlbauer, M.; Tomkovich, S.; Uronis, J.M.; Fan, T.-J.; Campbell, B.J.; Abujamel, T.; Dogan, B.; Rogers, A.B.; et al. Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota. Science 2012, 338, 120–123. [Google Scholar] [CrossRef] [Green Version]
  19. Cuevas-Ramos, G.; Petit, C.R.; Marcq, I.; Boury, M.; Oswald, E.; Nougayrède, J.-P. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc. Natl. Acad. Sci. USA 2010, 107, 11537–11542. [Google Scholar] [CrossRef] [Green Version]
  20. Wang, P.; Zhang, J.; Chen, Y.; Zhong, H.; Wang, H.; Li, J.; Zhu, G.; Xia, P.; Cui, L.; Li, J.; et al. ClbG in Avian Pathogenic Escherichia coli Contributes to Meningitis Development in a Mouse Model. Toxins 2021, 13, 546. [Google Scholar] [CrossRef]
  21. Tronnet, S.; Floch, P.; Lucarelli, L.; Gaillard, D.; Martin, P.; Serino, M.; Oswald, E. The Genotoxin Colibactin Shapes Gut Microbiota in Mice. mSphere 2020, 5, e00589-20. [Google Scholar] [CrossRef]
  22. Secher, T.; Payros, D.; Brehin, C.; Boury, M.; Watrin, C.; Gillet, M.; Bernard-Cadenat, I.; Menard, S.; Theodorou, V.; Saoudi, A.; et al. Oral Tolerance Failure upon Neonatal Gut Colonization with Escherichia coli Producing the Genotoxin Colibactin. Infect. Immun. 2015, 83, 2420–2429. [Google Scholar] [CrossRef] [Green Version]
  23. Bonnet, M.; Buc, E.; Sauvanet, P.; Darcha, C.; Dubois, D.; Pereira, B.; Déchelotte, P.; Bonnet, R.; Pezet, D.; Darfeuille-Michaud, A. Colonization of the human gut by E. coli and colorectal cancer risk. Clin. Cancer Res. 2014, 20, 859–867. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Cevallos, S.A.; Lee, J.-Y.; Tiffany, C.R.; Byndloss, A.J.; Johnston, L.; Byndloss, M.X.; Bäumler, A.J. Increased Epithelial Oxygenation Links Colitis to an Expansion of Tumorigenic Bacteria. mBio 2019, 10, e02244-19. [Google Scholar] [CrossRef] [Green Version]
  25. Dalmasso, G.; Cougnoux, A.; Delmas, J.; Darfeuille-Michaud, A.; Bonnet, R. The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment. Gut Microbes 2014, 5, 675–680. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Dejea, C.M.; Fathi, P.; Craig, J.M.; Boleij, A.; Taddese, R.; Geis, A.L.; Wu, X.; DeStefano Shields, C.E.; Hechenbleikner, E.M.; Huso, D.L.; et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 2018, 359, 592–597. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Dziubańska-Kusibab, P.J.; Berger, H.; Battistini, F.; Bouwman, B.A.M.; Iftekhar, A.; Katainen, R.; Cajuso, T.; Crosetto, N.; Orozco, M.; Aaltonen, L.A.; et al. Colibactin DNA-damage signature indicates mutational impact in colorectal cancer. Nat. Med. 2020, 26, 1063–1069. [Google Scholar] [CrossRef]
  28. Arnold, M.; Sierra, M.S.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017, 66, 683–691. [Google Scholar] [CrossRef] [Green Version]
  29. Lasry, A.; Zinger, A.; Ben-Neriah, Y. Inflammatory networks underlying colorectal cancer. Nat. Immunol. 2016, 17, 230–240. [Google Scholar] [CrossRef]
  30. Shin, N.-R.; Whon, T.W.; Bae, J.-W. Proteobacteria: Microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015, 33, 496–503. [Google Scholar] [CrossRef]
  31. Mayberry, J. The history of 5-ASA compounds and their use in ulcerative colitis--trailblazing discoveries in gastroenterology. J. Gastrointest. Liver Dis. 2013, 22, 375–377. [Google Scholar]
  32. Bajpai, M.; Seril, D.N.; Van Gurp, J.; Geng, X.; Alvarez, J.; Minacapelli, C.D.; Gorin, S.; Das, K.K.; Poplin, E.; Cheng, J.; et al. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. Dig. Dis. Sci. 2019, 64, 740–750. [Google Scholar] [CrossRef]
  33. Hauso, Ø.; Martinsen, T.C.; Waldum, H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scand. J. Gastroenterol. 2015, 50, 933–941. [Google Scholar] [CrossRef] [PubMed]
  34. Qiu, X.; Ma, J.; Wang, K.; Zhang, H. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: A systematic review with meta-analysis. Oncotarget 2017, 8, 1031–1045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Oh-Oka, K.; Kojima, Y.; Uchida, K.; Yoda, K.; Ishimaru, K.; Nakajima, S.; Hemmi, J.; Kano, H.; Fujii-Kuriyama, Y.; Katoh, R.; et al. Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon Receptor. Cell. Mol. Gastroenterol. Hepatol. 2017, 4, 135–151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Stolfi, C.; De Simone, V.; Pallone, F.; Monteleone, G. Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer. Int. J. Mol. Sci. 2013, 14, 17972–17985. [Google Scholar] [CrossRef] [Green Version]
  37. Rousseaux, C.; Lefebvre, B.; Dubuquoy, L.; Lefebvre, P.; Romano, O.; Auwerx, J.; Metzger, D.; Wahli, W.; Desvergne, B.; Naccari, G.C.; et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J. Exp. Med. 2005, 201, 1205–1215. [Google Scholar] [CrossRef]
  38. Stolfi, C.; Fina, D.; Caruso, R.; Caprioli, F.; Sarra, M.; Fantini, M.C.; Rizzo, A.; Pallone, F.; Monteleone, G. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem. Pharmacol. 2008, 75, 668–676. [Google Scholar] [CrossRef]
  39. Cevallos, S.A.; Lee, J.-Y.; Velazquez, E.M.; Foegeding, N.J.; Shelton, C.D.; Tiffany, C.R.; Parry, B.H.; Stull-Lane, A.R.; Olsan, E.E.; Savage, H.P.; et al. 5-Aminosalicylic Acid Ameliorates Colitis and Checks Dysbiotic Escherichia coli Expansion by Activating PPAR-γ Signaling in the Intestinal Epithelium. mBio 2021, 12, e03227-20. [Google Scholar] [CrossRef]
  40. Xu, J.; Chen, N.; Wu, Z.; Song, Y.; Zhang, Y.; Wu, N.; Zhang, F.; Ren, X.; Liu, Y. 5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. Front. Microbiol. 2018, 9, 1274. [Google Scholar] [CrossRef]
  41. Dahl, J.-U.; Gray, M.J.; Bazopoulou, D.; Beaufay, F.; Lempart, J.; Koenigsknecht, M.J.; Wang, Y.; Baker, J.R.; Hasler, W.L.; Young, V.B.; et al. The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation. Nat. Microbiol. 2017, 2, 16267. [Google Scholar] [CrossRef]
  42. Bowlin, M.Q.; Gray, M.J. Inorganic polyphosphate in host and microbe biology. Trends Microbiol. 2021, 29, 1013–1023. [Google Scholar] [CrossRef] [PubMed]
  43. Gray, M.J.; Wholey, W.-Y.; Wagner, N.O.; Cremers, C.M.; Mueller-Schickert, A.; Hock, N.T.; Krieger, A.G.; Smith, E.M.; Bender, R.A.; Bardwell, J.C.A.; et al. Polyphosphate is a Primordial Chaperone. Mol. Cell 2014, 53, 689–699. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Tang-Fichaux, M.; Chagneau, C.V.; Bossuet-Greif, N.; Nougayrède, J.-P.; Oswald, É.; Branchu, P. The Polyphosphate Kinase of Escherichia coli Is Required for Full Production of the Genotoxin Colibactin. mSphere 2020, 5, e01195-20. [Google Scholar] [CrossRef] [PubMed]
  45. Taieb, F.; Petit, C.; Nougayrède, J.-P.; Oswald, E. The Enterobacterial Genotoxins: Cytolethal Distending Toxin and Colibactin. EcoSal Plus 2016, 7, 1–21. [Google Scholar] [CrossRef] [PubMed]
  46. Xue, M.; Kim, C.S.; Healy, A.R.; Wernke, K.M.; Wang, Z.; Frischling, M.C.; Shine, E.E.; Wang, W.; Herzon, S.B.; Crawford, J.M. Structure elucidation of colibactin and its DNA cross-links. Science 2019, 365, eaax2685. [Google Scholar] [CrossRef] [PubMed]
  47. Vizcaino, M.I.; Crawford, J.M. The colibactin warhead crosslinks DNA. Nat. Chem. 2015, 7, 411–417. [Google Scholar] [CrossRef]
  48. Xue, M.; Wernke, K.M.; Herzon, S.B. Depurination of Colibactin-Derived Interstrand Cross-Links. Biochemistry 2020, 59, 892–900. [Google Scholar] [CrossRef] [Green Version]
  49. Secher, T.; Samba-Louaka, A.; Oswald, E.; Nougayrède, J.-P. Escherichia coli Producing Colibactin Triggers Premature and Transmissible Senescence in Mammalian Cells. PLoS ONE 2013, 8, e77157. [Google Scholar] [CrossRef] [Green Version]
  50. Boot, A.; Ng, A.; Chong, F.; Ho, S.-C.; Yu, W.; Tan, D.; Iyer, N.; Rozen, S. Characterization of colibactin-associated mutational signature in an Asian oral squamous cell carcinoma and in other mucosal tumor types. Genome Res. 2019, 30, 803–813. [Google Scholar] [CrossRef]
  51. Terlouw, D.; Suerink, M.; Boot, A.; van Wezel, T.; Nielsen, M.; Morreau, H. Recurrent APC Splice Variant c.835-8A>G in Patients With Unexplained Colorectal Polyposis Fulfilling the Colibactin Mutational Signature. Gastroenterology 2020, 159, 1612–1614.e5. [Google Scholar] [CrossRef]
  52. Berger, H.; Meyer, T.F. Mechanistic dissection unmasks colibactin as a prevalent mutagenic driver of cancer. Cancer Cell 2021, 39, 1439–1441. [Google Scholar] [CrossRef] [PubMed]
  53. Iftekhar, A.; Berger, H.; Bouznad, N.; Heuberger, J.; Boccellato, F.; Dobrindt, U.; Hermeking, H.; Sigal, M.; Meyer, T.F. Genomic aberrations after short-term exposure to colibactin-producing E. coli transform primary colon epithelial cells. Nat. Commun. 2021, 12, 1003. [Google Scholar] [CrossRef]
  54. Stidham, R.W.; Higgins, P.D.R. Colorectal Cancer in Inflammatory Bowel Disease. Clin. Colon Rectal Surg. 2018, 31, 168–178. [Google Scholar] [CrossRef]
  55. Eaden, J.A.; Abrams, K.R.; Mayberry, J.F. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001, 48, 526–535. [Google Scholar] [CrossRef] [Green Version]
  56. Ben-Neriah, Y.; Karin, M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011, 12, 715–723. [Google Scholar] [CrossRef] [PubMed]
  57. Grivennikov, S.; Karin, E.; Terzic, J.; Mucida, D.; Yu, G.-Y.; Vallabhapurapu, S.; Scheller, J.; Rose-John, S.; Cheroutre, H.; Eckmann, L.; et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15, 103–113. [Google Scholar] [CrossRef] [Green Version]
  58. Rokavec, M.; Öner, M.G.; Li, H.; Jackstadt, R.; Jiang, L.; Lodygin, D.; Kaller, M.; Horst, D.; Ziegler, P.K.; Schwitalla, S.; et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Investig. 2014, 124, 1853–1867. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Schwitalla, S.; Fingerle, A.A.; Cammareri, P.; Nebelsiek, T.; Göktuna, S.I.; Ziegler, P.K.; Canli, O.; Heijmans, J.; Huels, D.J.; Moreaux, G.; et al. Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties. Cell 2013, 152, 25–38. [Google Scholar] [CrossRef] [Green Version]
  60. Brentnall, T.A.; Crispin, D.A.; Rabinovitch, P.S.; Haggitt, R.C.; Rubin, C.E.; Stevens, A.C.; Burmer, G.C. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994, 107, 369–378. [Google Scholar] [CrossRef]
  61. Schwitalla, S.; Ziegler, P.K.; Horst, D.; Becker, V.; Kerle, I.; Begus-Nahrmann, Y.; Lechel, A.; Rudolph, K.L.; Langer, R.; Slotta-Huspenina, J.; et al. Loss of p53 in Enterocytes Generates an Inflammatory Microenvironment Enabling Invasion and Lymph Node Metastasis of Carcinogen-Induced Colorectal Tumors. Cancer Cell 2013, 23, 93–106. [Google Scholar] [CrossRef] [Green Version]
  62. Cooks, T.; Pateras, I.S.; Tarcic, O.; Solomon, H.; Schetter, A.J.; Wilder, S.; Lozano, G.; Pikarsky, E.; Forshew, T.; Rosenfeld, N.; et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013, 23, 634–646. [Google Scholar] [CrossRef] [Green Version]
  63. Tilstra, J.S.; Robinson, A.R.; Wang, J.; Gregg, S.Q.; Clauson, C.L.; Reay, D.P.; Nasto, L.A.; Croix, C.M.S.; Usas, A.; Vo, N.; et al. NF-κB inhibition delays DNA damage–induced senescence and aging in mice. J. Clin. Investig. 2012, 122, 2601–2612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Byndloss, M.X.; Pernitzsch, S.R.; Bäumler, A.J. Healthy hosts rule within: Ecological forces shaping the gut microbiota. Mucosal. Immunol. 2018, 11, 1299–1305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Jobin, C. Colorectal Cancer: Looking for Answers in the Microbiota. Cancer Discov. 2013, 3, 384–387. [Google Scholar] [CrossRef] [Green Version]
  66. Tomkovich, S.; Yang, Y.; Winglee, K.; Gauthier, J.; Mühlbauer, M.; Sun, X.; Mohamadzadeh, M.; Liu, X.; Martin, P.; Wang, G.P.; et al. Locoregional effects of microbiota in a preclinical model of colon carcinogenesis. Cancer Res. 2017, 77, 2620–2632. [Google Scholar] [CrossRef] [Green Version]
  67. Arthur, J.C.; Gharaibeh, R.Z.; Mühlbauer, M.; Perez-Chanona, E.; Uronis, J.M.; McCafferty, J.; Fodor, A.A.; Jobin, C. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 2014, 5, 4724. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Chanin, R.B.; Winter, M.G.; Spiga, L.; Hughes, E.R.; Zhu, W.; Taylor, S.J.; Arenales, A.; Gillis, C.C.; Büttner, L.; Jimenez, A.G.; et al. Epithelial-Derived Reactive Oxygen Species Enable AppBCX-Mediated Aerobic Respiration of Escherichia coli during Intestinal Inflammation. Cell Host Microbe 2020, 28, 780–788.e5. [Google Scholar] [CrossRef]
  69. Dubuquoy, L.; Jansson, E.A.; Deeb, S.; Rakotobe, S.; Karoui, M.; Colombel, J.-F.; Auwerx, J.; Pettersson, S.; Desreumaux, P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003, 124, 1265–1276. [Google Scholar] [CrossRef]
  70. Yamamoto-Furusho, J.K.; Jacintez-Cazares, M.; Furuzawa-Carballeda, J.; Fonseca-Camarillo, G. Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis. Dis. Markers 2014, 2014, 932530. [Google Scholar] [CrossRef]
  71. Litvak, Y.; Byndloss, M.X.; Bäumler, A.J. Colonocyte metabolism shapes the gut microbiota. Science 2018, 362, eaat9076. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Winter, S.E.; Winter, M.G.; Xavier, M.N.; Thiennimitr, P.; Poon, V.; Keestra, A.M.; Laughlin, R.C.; Gomez, G.; Wu, J.; Lawhon, S.D.; et al. Host-Derived Nitrate Boosts Growth of E. coli in the Inflamed Gut. Science 2013, 339, 708–711. [Google Scholar] [CrossRef] [Green Version]
  73. Hughes, E.R.; Winter, M.G.; Duerkop, B.A.; Spiga, L.; Furtado de Carvalho, T.; Zhu, W.; Gillis, C.C.; Büttner, L.; Smoot, M.P.; Behrendt, C.L.; et al. Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis. Cell Host Microbe 2017, 21, 208–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Zhu, W.; Winter, M.G.; Byndloss, M.X.; Spiga, L.; Duerkop, B.A.; Hughes, E.R.; Büttner, L.; de Lima Romão, E.; Behrendt, C.L.; Lopez, C.A.; et al. Precision editing of the gut microbiota ameliorates colitis. Nature 2018, 553, 208–211. [Google Scholar] [CrossRef] [PubMed]
  75. Zhu, W.; Miyata, N.; Winter, M.G.; Arenales, A.; Hughes, E.R.; Spiga, L.; Kim, J.; Sifuentes-Dominguez, L.; Starokadomskyy, P.; Gopal, P.; et al. Editing of the gut microbiota reduces carcinogenesis in mouse models of colitis-associated colorectal cancer. J. Exp. Med. 2019, 216, 2378–2393. [Google Scholar] [CrossRef]
  76. Dejea, C.M.; Wick, E.C.; Hechenbleikner, E.M.; White, J.R.; Welch, J.L.M.; Rossetti, B.J.; Peterson, S.N.; Snesrud, E.C.; Borisy, G.G.; Lazarev, M.; et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc. Natl. Acad. Sci. USA 2014, 111, 18321–18326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Motta, J.-P.; Allain, T.; Green-Harrison, L.E.; Groves, R.A.; Feener, T.; Ramay, H.; Beck, P.L.; Lewis, I.A.; Wallace, J.L.; Buret, A.G. Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2018, 24, 1493–1502. [Google Scholar] [CrossRef]
  78. Dubinsky, V.; Dotan, I.; Gophna, U. Carriage of Colibactin-producing Bacteria and Colorectal Cancer Risk. Trends Microbiol. 2020, 28, 874–876. [Google Scholar] [CrossRef]
  79. Buc, E.; Dubois, D.; Sauvanet, P.; Raisch, J.; Delmas, J.; Darfeuille-Michaud, A.; Pezet, D.; Bonnet, R. High Prevalence of Mucosa-Associated E. coli Producing Cyclomodulin and Genotoxin in Colon Cancer. PLoS ONE 2013, 8, e56964. [Google Scholar] [CrossRef] [Green Version]
  80. Johansson, M.E.V.; Gustafsson, J.K.; Holmén-Larsson, J.; Jabbar, K.S.; Xia, L.; Xu, H.; Ghishan, F.K.; Carvalho, F.A.; Gewirtz, A.T.; Sjövall, H.; et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 2014, 63, 281–291. [Google Scholar] [CrossRef]
  81. Raisch, J.; Rolhion, N.; Dubois, A.; Darfeuille-Michaud, A.; Bringer, M.-A. Intracellular colon cancer-associated Escherichia coli promote protumoral activities of human macrophages by inducing sustained COX-2 expression. Lab. Investig. 2015, 95, 296–307. [Google Scholar] [CrossRef] [Green Version]
  82. Yang, Y.; Gharaibeh, R.Z.; Newsome, R.C.; Jobin, C. Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer. Nat. Cancer 2020, 1, 723–734. [Google Scholar] [CrossRef] [PubMed]
  83. Ham, M.; Moss, A.C. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev. Clin. Pharmacol. 2012, 5, 113–123. [Google Scholar] [CrossRef]
  84. van de Meeberg, M.M.; Schultheiss, J.P.D.; Oldenburg, B.; Fidder, H.H.; Huitema, A.D.R. Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review. Digestion 2020, 101, 245–261. [Google Scholar] [CrossRef]
  85. Collier, H.O.; Francis, A.A.; McDonald-Gibson, W.J.; Saeed, S.A. Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites. Prostaglandins 1976, 11, 219–225. [Google Scholar] [CrossRef]
  86. Sharon, P.; Ligumsky, M.; Rachmilewitz, D.; Zor, U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978, 75, 638–640. [Google Scholar] [CrossRef]
  87. Egan, L.J.; Mays, D.C.; Huntoon, C.J.; Bell, M.P.; Pike, M.G.; Sandborn, W.J.; Lipsky, J.J.; McKean, D.J. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J. Biol. Chem. 1999, 274, 26448–26453. [Google Scholar] [CrossRef] [Green Version]
  88. Kaiser, G.C.; Yan, F.; Polk, D.B. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999, 116, 602–609. [Google Scholar] [CrossRef]
  89. Bos, C.L.; Diks, S.H.; Hardwick, J.C.H.; Walburg, K.V.; Peppelenbosch, M.P.; Richel, D.J. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 2006, 27, 2371–2382. [Google Scholar] [CrossRef] [Green Version]
  90. Parenti, S.; Ferrarini, F.; Zini, R.; Montanari, M.; Losi, L.; Canovi, B.; Ferrari, S.; Grande, A. Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells. Aliment. Pharmacol. Ther. 2010, 31, 108–119. [Google Scholar] [CrossRef]
  91. Khare, V.; Lyakhovich, A.; Dammann, K.; Lang, M.; Borgmann, M.; Tichy, B.; Pospisilova, S.; Luciani, G.; Campregher, C.; Evstatiev, R.; et al. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem. Pharmacol. 2013, 85, 234–244. [Google Scholar] [CrossRef] [Green Version]
  92. Munding, J.; Ziebarth, W.; Pox, C.P.; Ladigan, S.; Reiser, M.; Hüppe, D.; Brand, L.; Schmiegel, W.; Tannapfel, A.; Reinacher-Schick, A.C. The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the ß-catenin signaling pathway. Carcinogenesis 2012, 33, 637–643. [Google Scholar] [CrossRef] [Green Version]
  93. Wang, X.; Sun, Y.; Zhao, Y.; Ding, Y.; Zhang, X.; Kong, L.; Li, Z.; Guo, Q.; Zhao, L. Oroxyloside prevents dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB pathway through PPARγ activation. Biochem. Pharmacol. 2016, 106, 70–81. [Google Scholar] [CrossRef] [PubMed]
  94. Schwab, M.; Reynders, V.; Loitsch, S.; Shastri, Y.M.; Steinhilber, D.; Schröder, O.; Stein, J. PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 2008, 29, 1407–1414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Zhang, S.; Fu, J.; Dogan, B.; Scherl, E.J.; Simpson, K.W. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity. J. Antibiot. (Tokyo) 2018, 71, 950–961. [Google Scholar] [CrossRef] [PubMed]
  96. Rao, N.N.; Gómez-García, M.R.; Kornberg, A. Inorganic polyphosphate: Essential for growth and survival. Annu. Rev. Biochem. 2009, 78, 605–647. [Google Scholar] [CrossRef]
  97. Roewe, J.; Stavrides, G.; Strueve, M.; Sharma, A.; Marini, F.; Mann, A.; Smith, S.A.; Kaya, Z.; Strobl, B.; Mueller, M.; et al. Bacterial polyphosphates interfere with the innate host defense to infection. Nat. Commun. 2020, 11, 4035. [Google Scholar] [CrossRef]
  98. Zhang, Z.; Chen, F.; Shang, L. Advances in antitumor effects of NSAIDs. Cancer Manag. Res. 2018, 10, 4631–4640. [Google Scholar] [CrossRef] [Green Version]
  99. Bjarnason, I.; Scarpignato, C.; Holmgren, E.; Olszewski, M.; Rainsford, K.D.; Lanas, A. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology 2018, 154, 500–514. [Google Scholar] [CrossRef] [Green Version]
  100. Neville, N.; Roberge, N.; Ji, X.; Stephen, P.; Lu, J.L.; Jia, Z. A Dual-Specificity Inhibitor Targets Polyphosphate Kinase 1 and 2 Enzymes To Attenuate Virulence of Pseudomonas aeruginosa. mBio 2021, 12, e0059221. [Google Scholar] [CrossRef]
  101. Peng, L.; Zeng, L.; Jin, H.; Yang, L.; Xiao, Y.; Lan, Z.; Yu, Z.; Ouyang, S.; Zhang, L.; Sun, N. Discovery and antibacterial study of potential PPK1 inhibitors against uropathogenic E. coli. J. Enzym. Inhib. Med. Chem. 2020, 35, 1224–1232. [Google Scholar] [CrossRef] [PubMed]
  102. Zhu, Y.; Huang, W.; Lee, S.S.K.; Xu, W. Crystal structure of a polyphosphate kinase and its implications for polyphosphate synthesis. EMBO Rep. 2005, 6, 681–687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Toxins 13 00897 g001 550
Figure 1. Pks+ E. coli induce DNA damage and have a mutational impact leading to cancer formation. Colibactin is synthesized by an assembly line composed of non-ribosomal peptide synthetase (NRPS) and polyketide synthases (PKS) which are encoded by the pks island in E. coli. Colibactin produced by pks+ E. coli causes DNA inter-strand cross-links (ICLs) in a cell-to-cell contact dependent manner. ICLs in cellulo are converted into DNA double-strand breaks (DSBs) during the DNA-damage response or by depurination. DNA damages potentially can result in gene mutations which may trigger carcinogenesis.
Figure 1. Pks+ E. coli induce DNA damage and have a mutational impact leading to cancer formation. Colibactin is synthesized by an assembly line composed of non-ribosomal peptide synthetase (NRPS) and polyketide synthases (PKS) which are encoded by the pks island in E. coli. Colibactin produced by pks+ E. coli causes DNA inter-strand cross-links (ICLs) in a cell-to-cell contact dependent manner. ICLs in cellulo are converted into DNA double-strand breaks (DSBs) during the DNA-damage response or by depurination. DNA damages potentially can result in gene mutations which may trigger carcinogenesis.
Toxins 13 00897 g001
Toxins 13 00897 g002 550
Figure 2. Pks+ E. coli promote tumorigenesis in an inflamed environment. Adapted from reference [64].The color scale on the left indicates oxygen (O2) levels. (a) The healthy intestine harbors a diverse and dynamic microbial community (microbiota) which is dominated by obligate anaerobes (in white, green or blue); the expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) in intestinal epithelial cells (IECs) activates mitochondrial bioenergetics that consume O2, and thereby maintains epithelial hypoxia (O2 level < 1%). (b) In the inflamed intestine, nuclear factor kappa B (NF-κB) plays an important role for the transition from inflammation to malignancy. NF-κB induces interleukin 6 (IL-6) which promotes IEC proliferation, the inhibition of apoptosis, and other pro-tumorigenic pathway; the activation of tumor necrosis factor (TNF) enhances the activation of NF-κB, resulting in de-differentiation of IEC and facilitation of tumor initiation. NF-κB induces the generation of reactive oxygen species (ROS) which increase epithelial oxygenation. A lower PPAR-γ expression also leads to a higher epithelial oxygenation. The increased O2 level benefits the expansion of facultative anaerobic Enterobacteriaceae, including pks+ E. coli (in yellow; other Enterobacteriaceae are in orange). Inducible nitric oxide synthase (iNOS) is expressed at a high level during intestinal inflammation, resulting in an elevated production of nitric oxide (NO) which generates nitrate (NO3−); NO3− boosts the growth of pks+ E. coli. The increased concentration of microbiota-derived formate enhances E. coli fitness in the inflamed intestine. Biofilm formation and intestinal barrier dysfunction are often found in colitis, which promote pks+ E. coli contact with IEC and invasion. Colibactin produced by pks+ E. coli causes DNA damages which lead to the mutations in genes, such as APC and miR-34a. This results in colorectal cancer (CRC) cells which are characterized by Wnt-independent growth, enhanced proliferation and impaired differentiation.
Figure 2. Pks+ E. coli promote tumorigenesis in an inflamed environment. Adapted from reference [64].The color scale on the left indicates oxygen (O2) levels. (a) The healthy intestine harbors a diverse and dynamic microbial community (microbiota) which is dominated by obligate anaerobes (in white, green or blue); the expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) in intestinal epithelial cells (IECs) activates mitochondrial bioenergetics that consume O2, and thereby maintains epithelial hypoxia (O2 level < 1%). (b) In the inflamed intestine, nuclear factor kappa B (NF-κB) plays an important role for the transition from inflammation to malignancy. NF-κB induces interleukin 6 (IL-6) which promotes IEC proliferation, the inhibition of apoptosis, and other pro-tumorigenic pathway; the activation of tumor necrosis factor (TNF) enhances the activation of NF-κB, resulting in de-differentiation of IEC and facilitation of tumor initiation. NF-κB induces the generation of reactive oxygen species (ROS) which increase epithelial oxygenation. A lower PPAR-γ expression also leads to a higher epithelial oxygenation. The increased O2 level benefits the expansion of facultative anaerobic Enterobacteriaceae, including pks+ E. coli (in yellow; other Enterobacteriaceae are in orange). Inducible nitric oxide synthase (iNOS) is expressed at a high level during intestinal inflammation, resulting in an elevated production of nitric oxide (NO) which generates nitrate (NO3−); NO3− boosts the growth of pks+ E. coli. The increased concentration of microbiota-derived formate enhances E. coli fitness in the inflamed intestine. Biofilm formation and intestinal barrier dysfunction are often found in colitis, which promote pks+ E. coli contact with IEC and invasion. Colibactin produced by pks+ E. coli causes DNA damages which lead to the mutations in genes, such as APC and miR-34a. This results in colorectal cancer (CRC) cells which are characterized by Wnt-independent growth, enhanced proliferation and impaired differentiation.
Toxins 13 00897 g002
Toxins 13 00897 g003 550
Figure 3. The pleiotropic effects of mesalamine on the host and on pks+ E. coli. Mesalamine has effects on both host cells and pks+ E. coli. Mesalamine inhibits the growth and enhances the death of CRC cells; mesalamine interferes with the activation of nuclear factor kappa B (NF-κB) which plays an important role for the transition from inflammation to malignancy; and, mesalamine-driven PPAR-γ activation restores mitochondrial bioenergetics that consume O2, and thereby restore epithelial hypoxia. Mesalamine limits the expansion of pks+ E. coli by reducing epithelial oxygenation or directly inhibiting the aerobic growth. Mesalamine is an inhibitor of polyphosphate kinase (PPK), by which mesalamine may inhibit various of bacterial abilities, such as persistence, biofilm formation and interference with immune cells; and mesalamine inhibits colibactin production in a PPK-dependent and independent way.
Figure 3. The pleiotropic effects of mesalamine on the host and on pks+ E. coli. Mesalamine has effects on both host cells and pks+ E. coli. Mesalamine inhibits the growth and enhances the death of CRC cells; mesalamine interferes with the activation of nuclear factor kappa B (NF-κB) which plays an important role for the transition from inflammation to malignancy; and, mesalamine-driven PPAR-γ activation restores mitochondrial bioenergetics that consume O2, and thereby restore epithelial hypoxia. Mesalamine limits the expansion of pks+ E. coli by reducing epithelial oxygenation or directly inhibiting the aerobic growth. Mesalamine is an inhibitor of polyphosphate kinase (PPK), by which mesalamine may inhibit various of bacterial abilities, such as persistence, biofilm formation and interference with immune cells; and mesalamine inhibits colibactin production in a PPK-dependent and independent way.
Toxins 13 00897 g003
Toxins 13 00897 g004 550
Figure 4. PPK inhibitors inhibit PPK activity to repress various bacterial activities. Adapted from reference [101]. PPK is involved in many bacterial abilities, such as genotoxicity, resistance to oxidative stress, biofilm formation, biofilm formation, persistence, virulence, motility, and interfere with macrophage functions etc. PPK inhibitors have been shown to inhibit some of these bacterial abilities in vitro or/and in vivo. The crystal structure of polyphosphate kinase (PPK) was downloaded from Protein Data Bank under the accession codes 1XDO [102].
Figure 4. PPK inhibitors inhibit PPK activity to repress various bacterial activities. Adapted from reference [101]. PPK is involved in many bacterial abilities, such as genotoxicity, resistance to oxidative stress, biofilm formation, biofilm formation, persistence, virulence, motility, and interfere with macrophage functions etc. PPK inhibitors have been shown to inhibit some of these bacterial abilities in vitro or/and in vivo. The crystal structure of polyphosphate kinase (PPK) was downloaded from Protein Data Bank under the accession codes 1XDO [102].
Toxins 13 00897 g004
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Tang-Fichaux, M.; Branchu, P.; Nougayrède, J.-P.; Oswald, E. Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet? Toxins 2021, 13, 897. https://doi.org/10.3390/toxins13120897

AMA Style

Tang-Fichaux M, Branchu P, Nougayrède J-P, Oswald E. Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet? Toxins. 2021; 13(12):897. https://doi.org/10.3390/toxins13120897

Chicago/Turabian Style

Tang-Fichaux, Min, Priscilla Branchu, Jean-Philippe Nougayrède, and Eric Oswald. 2021. "Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet?" Toxins 13, no. 12: 897. https://doi.org/10.3390/toxins13120897

APA Style

Tang-Fichaux, M., Branchu, P., Nougayrède, J.-P., & Oswald, E. (2021). Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet? Toxins, 13(12), 897. https://doi.org/10.3390/toxins13120897

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop